Background \ud We report a case of a 53 year old lady recently commenced on etanercept, an anti-TNF (tumour necrosis factor) therapy for rheumatoid arthritis presenting with \ud confusion, pyrexia and an erythematous rash. \ud \ud Case presentation \ud A lumbar puncture was highly suggestive of bacterial meningitis, but CSF cultures produced no growth, and polymerase chain reactions (PCR) for all previously reported bacterial, fungal and viral causes of meningitis were negative. \ud \ud Conclusions \ud This case report describes aseptic meningitis as a previously unreported complication of etanercept therapy, and serves as a reminder of the rare but potentially lifethreatening risk of serious infections in patients taking anti-TNF thera...
Presentation A 60-year-old male taking etanercept for ankylosing spondylitis was admitted to hospit...
TNF-alpha blockers represent one of the most important therapeutic strategies for rheumatoid arthrit...
We describe a patient with refractory cutaneous polyarteritis nodosa (CPAN) with hepatitis B virus (...
International audienceBACKGROUND: TNFα blockers have drastically improved rheumatoid arthritis progn...
We report a 65-year-old man who had repetitive seizures 6 months after receiving etanercept, methotr...
Etanercept is a competitive inhibitor of tumor necrosis factor-alpha (TNF-α) a polypeptide hormone, ...
Background. A 70-year-old female with active rheumatoid arthritis (RA) was administered etanercept t...
Long-term extension studies and observational drug registers have revealed an increased risk of seri...
Vasculitis is a heterogeneous group of disorders characterized by the presence of necrotic inflammat...
There are few case reports documenting a new onset of demyelinating processes in patients receiving ...
Etanercept is a soluble receptor fusion protein that inhibits tumor necrosis factor-alpha(TNF-&alpha...
Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory approval for use in rheum...
Etanercept is an inhibitor of the pro-inflammatory and immunor-egulatory cytokine tumor necrosis fac...
Tumor necrosis factor-alpha (TNFalpha)-blocking agents are immunomodulating agents introduced for tr...
Tumor necrosis factor-?#6184;TNF-?#6752;is a major proinflammatory cytokine involved in the pathophy...
Presentation A 60-year-old male taking etanercept for ankylosing spondylitis was admitted to hospit...
TNF-alpha blockers represent one of the most important therapeutic strategies for rheumatoid arthrit...
We describe a patient with refractory cutaneous polyarteritis nodosa (CPAN) with hepatitis B virus (...
International audienceBACKGROUND: TNFα blockers have drastically improved rheumatoid arthritis progn...
We report a 65-year-old man who had repetitive seizures 6 months after receiving etanercept, methotr...
Etanercept is a competitive inhibitor of tumor necrosis factor-alpha (TNF-α) a polypeptide hormone, ...
Background. A 70-year-old female with active rheumatoid arthritis (RA) was administered etanercept t...
Long-term extension studies and observational drug registers have revealed an increased risk of seri...
Vasculitis is a heterogeneous group of disorders characterized by the presence of necrotic inflammat...
There are few case reports documenting a new onset of demyelinating processes in patients receiving ...
Etanercept is a soluble receptor fusion protein that inhibits tumor necrosis factor-alpha(TNF-&alpha...
Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory approval for use in rheum...
Etanercept is an inhibitor of the pro-inflammatory and immunor-egulatory cytokine tumor necrosis fac...
Tumor necrosis factor-alpha (TNFalpha)-blocking agents are immunomodulating agents introduced for tr...
Tumor necrosis factor-?#6184;TNF-?#6752;is a major proinflammatory cytokine involved in the pathophy...
Presentation A 60-year-old male taking etanercept for ankylosing spondylitis was admitted to hospit...
TNF-alpha blockers represent one of the most important therapeutic strategies for rheumatoid arthrit...
We describe a patient with refractory cutaneous polyarteritis nodosa (CPAN) with hepatitis B virus (...